Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854044 | 0.80 | CYSLTR1 (0.45) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL12844112 | 0.74 | PDE1B (0.55) | PDE10ACYP1A2 | |
| SCHEMBL10465701 | 0.70 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL7459197 | 0.70 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10533356 | 0.70 | PDE10A (0.52) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| Hydrochloric Acid SCHEMBL9688827 | 0.70 | CYSLTR1 (0.45) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL7454262 | 0.69 | PDE10A (0.57) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL10547704 | 0.68 | PDE10A (0.64) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL9363352 | 0.68 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL1004347 | 0.68 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |